Muutke küpsiste eelistusi

E-raamat: Regulation of Biotechnological Risks in a Multi-Level System: An Analysis of the EU Regulation of Genome Edited Plants in light of WTO Law and CETA

  • Formaat - PDF+DRM
  • Hind: 172,28 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

This book offers an in-depth analysis of the EU regulation of genome edited plants and its compatibility with WTO law and the Comprehensive Economic Trade Agreement (CETA). It analyses in detail whether the EU authorisation procedures, labelling requirements and the EU's opt-out mechanism and its application to genome edited plants are compatible with the EU's obligations under the Agreement on Sanitary and Phytosanitary Measures (SPS Agreement), the Agreement on Technical Barriers to Trade (TBT Agreement), the General Agreement on Tariffs and Trade (GATT) and CETA.  Based on this analysis, the EU Commission's proposal for a new regulation on plants produced by certain new genomic techniques is discussed. Also, the book provides suggestions to further improve the EU Commission's proposal.  The book's analysis is not only relevant for legal researchers in the field of biotechnology and international economic law, but also discusses regulatory aspects that are highly relevant for the scientific and industrial sector involved in biotechnology.

Introduction.- Scientific Background.- The European Court of Justices
Decision on Genome Editing.- The Regulation of Genetically Modified Plants in
the European Union.- The EUs Obligations under WTO law and CETA.- EU
Regulations on Genome Edited Plants under WTO Law and CETA.- The Future of
Genome Edited Plants in the EU.- Concluding Remarks.- Summary of Results.
Elisabeth Anna Lümkea Andersen graduated in law from the University of Freiburg in 2018. Already during her studies, she focused on public international law and the interrelations of science and law especially in the field of German and international patent law. From 2018 to 2022, she has been a legal researcher at the Centre for Integrative Biological Signalling Studies, Cluster of Excellence, University of Freiburg. Her research focused on international and EU biotechnology law and its interactions with WTO law and CETA as well as public international law. For her PhD thesis which she realised as part of the CIBSS project, she especially focused on the regulation of genome editing techniques and its application to plants in EU law, WTO law and CETA, also examining the EU Commission's plans to adopt new regulations in this field.